There's a phrase that shapes cancer treatment more than most of us realise: “the average patient”. It's who a treatment plan is actually built for - not for the patient specifically, but a statistical composite drawn from clinical trials. And once a patient starts on the recommended drug, it is often eight to twelve weeks before a scan tells you whether it was ever going to work for your tumour, specifically. And the odds aren't great to begin with - roughly 19 out of 20 cancer drugs that enter human trials never make it to approval. Today we're talking to Dr Christoph Meinert, co-founder & CEO of Brisbane-based Gelomics, who’s trying to close that gap. How? He’s using AI to build a digital stand-in for an individual patient's own tumour, so doctors can test treatments on it before they ever test them on the human.

Learn more

This episode is sponsored by Google, but they have had no editorial influence over the content we are sharing in today’s podcast.

Host: Sam Koslowski
Guest: Dr Christoph Meinert, Gelomics co-founder & CEO
Producer: Orla Maher 

Want to support The Daily Aus? That's so kind! The best way to do that is to click ‘follow’ on Spotify or Apple and to leave us a five-star review. We would be so grateful.

The Daily Aus is a media company focused on delivering accessible and digestible news to young people. We are completely independent.

Want more from TDA?
Subscribe to The Daily Aus newsletter
Subscribe to The Daily Aus’ YouTube Channel

Have feedback for us?
We’re always looking for new ways to improve what we do. If you’ve got feedback, we’re all ears. Tell us here.

Shot on Fujifilm.